Breaking News, Financial News

Financial Report: Biogen Idec 4Q

Growth was driven by Tysabri sales, up 74% to $156 million in the quarter and up 156% to $589 million for the year.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec 4Q Revenues: $1.1 billion (+20%) 4Q Earnings: $207.0 million (+3%) FY Revenues: $4.1 billion (+29%) FY Earnings: $783.0 million (+23%) Comments: Growth was driven by Tysabri sales, up 74% to $156 million in the quarter and up 156% to $589 million for the year. In the quarter, Biogen recognized revenue of $156 million related to Tysabri, consisting of $53 million related to Elan sales in the U.S. and $103 million related sales in rest of world markets. Avonex sales were...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters